In one paragraphArticle in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Miguel M MadeiraMolecular and Cellular Pharmacology Graduate Program, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY 11794.
Zachary HageMolecular and Cellular Pharmacology Graduate Program, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY 11794.
Dimitris KoliatsisMolecular and Cellular Pharmacology Graduate Program, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY 11794.
Alexandros G KokkosisMolecular and Cellular Pharmacology Graduate Program, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY 11794.ORCID 0000-0001-5148-3290 Kimberly NnahScholars in Biomedical Sciences Program, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY 11794.ORCID 0000-0002-0518-9004 Alexander J RheeMolecular and Cellular Pharmacology Graduate Program, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY 11794.ORCID 0009-0004-8881-3555 Gilbert J RahmeMolecular and Cellular Pharmacology Graduate Program, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY 11794.ORCID 0000-0001-6060-1279 Katherine KamvisiosDepartment of Pharmacological Sciences, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY 11794.
Antonis E KoromilasLady Davis Institute for Medical Research, Sir Mortimer B, Davis-Jewish General Hospital and Gerald Bronfman Department of Oncology, Faculty of Medicine, McGill University, Montreal, QC H3T 1E2, Canada.ORCID 0000-0003-1972-0799 Barbara RosatiDepartment of Physiology and Biophysics Renaissance School of Medicine at Stony Brook University, Stony Brook, NY 11794.ORCID 0000-0002-2725-0478 Stella E TsirkaMolecular and Cellular Pharmacology Graduate Program, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY 11794.ORCID 0000-0003-0022-1770 Funding
IRACDA - The New York Consortium for the Advancement of Postdoctoral Scholars (NY CAPS)Phase IIK12GM102778 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI Carol A. Carter, Karian Janice Wright · 2012 to 2026
$13.1MTraining Program in Pharmacological SciencesT32GM007518 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI GARCIA-DIAZ, MIGUEL · 1985 to 2021
$5.4MA translational study of neuroinflammatory depression: Understanding mechanism and evaluation of a novel pharmacologic intervention - Diversity Administrative supplement for Kimberly NnahR01MH123093 · NIMH · STATE UNIVERSITY NEW YORK STONY BROOK · PI DELORENZO, CHRISTINE, PARSEY, RAMIN V. · 2020 to 2024
$3.8MTraining Program in Pharmacological SciencesT32GM144304 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI HOLLY A COLOGNATO · 2022 to 2026
$1.8MScholars in BioMedical Sciences (SBMS) Training ProgramT32GM148331 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI Styliani-Anna (Stella) E Tsirka · 2024 to 2026
$695kScholars in BioMedical Sciences (SBMS) Training ProgramT32GM127253 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI TSIRKA, STYLIANI-ANNA (STELLA) E · 2018 to 2022
$689kModeling and Dissecting Epigenetic Drivers of GliomagenesisR00CA267082 · NCI · STATE UNIVERSITY NEW YORK STONY BROOK · PI RAHME, GILBERT J · 2023 to 2025
$688kAmerican Heart Association (AHA) 19PRE34370044HHS | NIH (NIH) K12GM102778HHS | NIH (NIH) R00CA267082HHS | NIH (NIH) R01MH123093HHS | NIH (NIH) R01MH123093S1HHS | NIH (NIH) R01MH123093W1HHS | NIH (NIH) T32GM007518HHS | NIH (NIH) T32GM127253NCI NIH HHS R00 CA267082NIGMS NIH HHS K12 GM102778NIGMS NIH HHS T32 GM007518NIGMS NIH HHS T32 GM127253NIGMS NIH HHS T32 GM144304NIGMS NIH HHS T32 GM148331NIMH NIH HHS R01 MH123093SUNY | Stony Brook University (SBU) Snyder FellowshipSUNY | Stony Brook University (SBU) URECA
6 · The paper itselfAbstract
Chronic psychosocial stress is a major precipitant of Major Depressive Disorder (MDD), yet the glial mechanisms that translate sustained stress into maladaptive myelin and immune changes remain unclear. Using chronic social defeat stress and single-nucleus RNA sequencing of anterior medial PFC (mPFC) oligodendroglia, we identified a mature-oligodendrocyte cluster almost exclusively from stress-susceptible animals, marked by immune genes (MHCII) and upregulated Pde4b. Integration with a human MDD single-nucleus RNA sequencing dataset confirmed a conserved immune-like oligodendrocyte (ImOL) subset coexpressing Plp1 and Cd74 and enriched for Pde4b. Mechanistically, PDE4 inhibition with crisaborole elevated cAMP-PKA-CREB signaling, blocked IFNγ-induced MHCII expression, and engaged the eIF2α-ATF4/CHOP arm of the integrated stress response (ISR). In vivo modulation of the ISR with ISRIB or guanabenz bidirectionally controlled ImOL prevalence and stress-related behaviors. These findings position Pde4b-cAMP-ISR signaling as a regulator of oligodendroglial immune phenotypes and a promising target to modulate myelination and neuroinflammation in stress-related disorders.
Indexed as
Histocompatibility Antigens Class IIMajor Depressive DisorderOligodendrogliaPsychosocial FunctioningSocial DefeatStress, PsychologicalAnimalsBoron CompoundsCyclic AMPCyclic AMP-Dependent Protein KinasesCyclic AMP Response Element-Binding ProteinCyclic Nucleotide Phosphodiesterases, Type 4Datasets as TopicHumansInterferon-gammaMiceBoron CompoundscrisaboloreCyclic AMPCyclic AMP-Dependent Protein KinasesCyclic AMP Response Element-Binding ProteinCyclic Nucleotide Phosphodiesterases, Type 4Histocompatibility Antigens Class IIInterferon-gammaPDE4B protein, mousePhosphodiesterase 4 Inhibitorshypomyelinationimmune oligodendrocytesmajor depressive disorderneuroinflammationoligodendroglia
Identifiers
PMID42085152
PMCPMC13168534
What OpenQuestion holds
Textmetadata
Read underepoch 390